光环
偏头痛
医学
先兆偏头痛
麻醉
安慰剂
皮质扩散性抑郁症
替代医学
病理
作者
Andreas Vinther Thomsen,Mohammad Al‐Mahdi Al‐Karagholi,Anders Hougaard,Sisse Rye Ostrowski,Ole Birger Pedersen,Thomas Hansen,Messoud Ashina
出处
期刊:Cephalalgia
[SAGE Publishing]
日期:2024-03-01
卷期号:44 (3)
被引量:20
标识
DOI:10.1177/03331024241237247
摘要
Background/Hypothesis Experimental provocation studies have yielded important insights in migraine pathophysiology. Levcromakalim has been previously shown to induce migraine-like attacks with and without aura. In this study, we aim to further explore the migraine aura-inducing potential of levcromakalim. Methods In a double-blind, randomized, placebo-controlled cross-over study, 27 adult participants with migraine with aura received intravenous infusions of levcromakalim and saline. Headache, aura and associated symptoms were evaluated for 24 hours following administration of the study drug. The primary endpoint was occurrence of migraine-like attacks with or without aura in the 24-hour observation period. Results Thirteen participants developed migraine-like attacks on the active day only (P = 0.0098), and four participants developed aura on the active day only (P = 0.68). The median time to onset of migraine-like headache was three hours, and the median time to onset of aura was 27.5 minutes. Conclusion/Interpretation Our findings affirm the potent migraine-inducing effect of levcromakalim. We observed a lower induction-rate of migraine aura than previously reported. Further studies are warranted to identify predictors of migraine aura following levcromakalim. ClinicalTrials.gov identifier NCT04905654
科研通智能强力驱动
Strongly Powered by AbleSci AI